{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:39:40Z","timestamp":1786995580049,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.pharmthera.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T22:52:02Z","timestamp":1533336722000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Targeting TLRs and the inflammasome in systemic sclerosis"],"prefix":"10.1016","volume":"192","author":[{"given":"John","family":"Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.08.003_bb0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/iji.12212","article-title":"IL-1A rs1800587, IL-1B rs1143634 and IL-1R1 rs2234650 polymorphisms in Iranian patients with systemic sclerosis","volume":"42","author":"Abtahi","year":"2015","journal-title":"International Journal of Immunogenetics"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0010","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/jid.2010.120","article-title":"Epithelial cells promote fibroblast activation via IL-1\u03b1 in systemic sclerosis","volume":"130","author":"Aden","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13075-017-1331-z","article-title":"Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis","volume":"19","author":"Artlett","year":"2017","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0025","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.30568","article-title":"The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis","volume":"63","author":"Artlett","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl. 10","key":"10.1016\/j.pharmthera.2018.08.003_bb0030","article-title":"Immunoablation followed by autologous stem cell transplantation in systemic sclerosis patients decreases significantly the interferon signature","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00403-005-0594-4","article-title":"Toll-like receptor 2 (TLR2) mediates intracellular signalling in human keratinocytes in response to Malassezia furfur","volume":"297","author":"Baroni","year":"2006","journal-title":"Archives of Dermatological Research"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","article-title":"Toll-like receptor 4 signaling augments transforming growth factor-\u03b2 responses: A novel mechanism for maintaining and amplifying fibrosis in scleroderma","volume":"182","author":"Bhattacharyya","year":"2013","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0045","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1038\/ncomms11703","article-title":"Tenascin-C drives persistence of organ fibrosis","volume":"7","author":"Bhattacharyya","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/1756-185X.13035","article-title":"Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease","volume":"20","author":"Boulos","year":"2017","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.33325","article-title":"A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators","volume":"64","author":"Broen","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0060","doi-asserted-by":"crossref","first-page":"2304218","DOI":"10.1155\/2017\/2304218","article-title":"Association of Polymorphisms in toll-like receptors 4 and 9 with autoimmune thyroid disease in Korean pediatric patients","volume":"2017","author":"Cho","year":"2017","journal-title":"International Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0065","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.celrep.2016.05.009","article-title":"Diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms","volume":"15","author":"Choi","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","article-title":"Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus","volume":"25","author":"Christensen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-016-1054-6","article-title":"miR-155 in the progression of lung fibrosis in systemic sclerosis","volume":"18","author":"Christmann","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0080","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/annrheumdis-2012-201958","article-title":"Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: Role of serum factors","volume":"72","author":"Ciechomska","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780360113","article-title":"Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients","volume":"36","author":"Clements","year":"1993","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small molecule inhibitior of the NLRP3 inflammasome is a potential therapeutic for inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0095","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"British Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti\u2013transforming growth factor \u03b21 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-017-0630-3","article-title":"Innate immunity in systemic sclerosis","volume":"19","author":"Dowson","year":"2017","journal-title":"Current Rheumatology Reports"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0110","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/art.39655","article-title":"Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor beta-dependent fibroblast activation","volume":"68","author":"Fang","year":"2016","journal-title":"Arthritis & Rhematology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-017-1237-9","article-title":"Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes","volume":"19","author":"Farina","year":"2017","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0120","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/rheumatology\/38.10.992","article-title":"Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy","volume":"38","author":"Filaci","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0125","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: A phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1468-3083.2011.04372.x","article-title":"Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis","volume":"27","author":"Garcia-Rodriguez","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10067-017-3880-6","article-title":"Toll-like receptor 9 in systemic sclerosis patients: Relation to modified Rodnan skin score, disease severity, and functional status","volume":"37","author":"Gheita","year":"2017","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0140","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","article-title":"Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors","volume":"140","author":"Gilliet","year":"2004","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0145","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1111\/bph.12797","article-title":"A novel 1,2-benzenediamine derivative FC-99 suppresses TLR3 expression and ameliorates disease symptoms in a mouse model of sepsis","volume":"171","author":"Gong","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1203\/00006450-197804001-00708","article-title":"703 progressive systemic sclerosis (PSS)-like syndrome following bone marrow transplantation","volume":"12","author":"Herzog","year":"1978","journal-title":"Pediatric Research"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0155","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1165\/rcmb.2008-0182OC","article-title":"Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice","volume":"41","author":"Hoshino","year":"2009","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0160","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0165","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s12026-016-8797-7","article-title":"Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis: An independent case-control study and a meta-analysis","volume":"64","author":"Huang","year":"2016","journal-title":"Immunologic Research"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0170","first-page":"81","article-title":"Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis","volume":"31","author":"Hutyrov\u00e1","year":"2004","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0175","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0180","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI4304","article-title":"Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A","volume":"103","author":"Kawaguchi","year":"1999","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0185","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/bbrc.1993.1024","article-title":"Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1\u03b2","volume":"190","author":"Kawaguchi","year":"1993","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.10736","article-title":"Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population","volume":"48","author":"Kawaguchi","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0200","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/jid.2009.302","article-title":"IL-18 downregulates collagen production in human dermal fibroblasts via the ERK pathway","volume":"130","author":"Kim","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0205","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0210","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11596-007-0226-7","article-title":"Expression of TLR9 and its mRNA in the lesions of lichen planus","volume":"27","author":"Li","year":"2007","journal-title":"Journal of Huazhong University of Science and Technology. Medical Sciences"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.pharmthera.2013.03.003","article-title":"Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases","volume":"138","author":"Li","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0225","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/eji.201445219","article-title":"Increased expression of TLR2 in CD4(+) T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications","volume":"45","author":"Liu","year":"2015","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0230","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0235","first-page":"997","article-title":"Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis","volume":"34","author":"Mattuzzi","year":"2007","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0240","first-page":"1","article-title":"Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis","author":"Melsens","year":"2017","journal-title":"Acta Clinica Belgica"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0245","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.4049\/jimmunol.174.10.6137","article-title":"TGF-alpha regulates TLR expression and function on epidermal keratinocytes","volume":"174","author":"Miller","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0250","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0255","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2014A retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0260","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/CS20130367","article-title":"Innate immunity in systemic sclerosis pathogenesis","volume":"126","author":"O'Reilly","year":"2014","journal-title":"Clinical Science (London, England)"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0265","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20140467","article-title":"Pound the alarm: Danger signals in rheumatic diseases","volume":"128","author":"O'Reilly","year":"2015","journal-title":"Clinical Science (London, England)"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0270","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.12260","article-title":"Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-\u03baB","volume":"143","author":"O'Reilly","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0275","first-page":"S117","article-title":"Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and Behcet's diseases","volume":"33","author":"Ortiz-Fernandez","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0280","first-page":"613","article-title":"Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy","volume":"25","author":"Paone","year":"2007","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0285","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fimmu.2016.00578","article-title":"Increased toll-like receptors activity and TLR ligands in patients with autoimmune thyroid diseases","volume":"7","author":"Peng","year":"2016","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaf3596","article-title":"Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages","volume":"9","author":"Piccinini","year":"2016","journal-title":"Science Signal"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0295","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0300","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1083\/jcb.106.2.311","article-title":"Modulation of fibroblast functions by interleukin 1: Increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta","volume":"106","author":"Postlethwaite","year":"1988","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0305","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","article-title":"Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: A phase II multicentre randomized double-blinded controlled trial","volume":"167","author":"Prey","year":"2012","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165246","article-title":"Dietary interventions in multiple sclerosis: Development and pilot-testing of an evidence based patient education program","volume":"11","author":"Riemann-Lorenz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0315","doi-asserted-by":"crossref","first-page":"15136","DOI":"10.1073\/pnas.1520997112","article-title":"Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis","volume":"112","author":"Saigusa","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0320","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/infdis\/jit133","article-title":"Toll-like receptor 1 N248S single-nucleotide polymorphism is associated with leprosy risk and regulates immune activation during mycobacterial infection","volume":"208","author":"de Sales Marques","year":"2013","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0325","first-page":"294","article-title":"Interleukin-1 production by mononuclear cells from patients with scleroderma","volume":"60","author":"Sandborg","year":"1985","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0335","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaut.2010.05.004","article-title":"TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy","volume":"35","author":"Summers","year":"2010","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0340","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38901","article-title":"Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis","volume":"67","author":"Takahashi","year":"2015","journal-title":"Arthritis & Rhematology"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0345","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0350","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/art.1780330619","article-title":"Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma","volume":"33","author":"Umehara","year":"1990","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13353-017-0415-4","article-title":"Expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells from patients with systemic sclerosis","volume":"59","author":"Vre\u0107a","year":"2017","journal-title":"Journal of Applied Genetics"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0360","series-title":"Gadolinium compounds signaling through TLR 4 and TLR 7 in normal human macrophages: Establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis","volume":"Vol. 189","author":"Wermuth","year":"2012"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0365","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: Potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0370","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1136\/annrheumdis-2015-207405","article-title":"Nucleosome in patients with systemic sclerosis: Possible association with immunological abnormalities via abnormal activation of T and B cells","volume":"75","author":"Yoshizaki","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0375","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.003_bb0380","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.tripleo.2010.01.006","article-title":"Expression of Toll-like receptors 7, 8, and 9 in primary Sjogren's syndrome","volume":"109","author":"Zheng","year":"2010","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:35:26Z","timestamp":1717209326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818301359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":76,"alternative-id":["S0163725818301359"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting TLRs and the inflammasome in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}